Soliris MG denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for soliris mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Soliris (Eculizumab) as Experimental

An experimental or investigational denial means Aetna concluded that Soliris (eculizumab) lacks sufficient evidence of safety and effectiveness for the specific indication being treated, or that the use falls outside what the plan considers established clinical practice. For a drug like Soliris, which carries FDA approval for multiple rare and serious conditions, this denial most commonly occurs when the prescribed indication is an off-label use, when the condition is rare enough that the reviewer applied the wrong evidentiary standard, or when the plan's policy has not been updated to reflect current guideline recommendations.

Because many Soliris indications involve life-threatening complement-mediated diseases, an experimental denial often rises to the level of urgency that supports an expedited appeal.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Most plans allow 180 days from the denial date to initiate an internal appeal.
• External review (ACA §2719): After exhausting internal appeals, request independent external review. The window is generally approximately four months from final internal denial. Expedited external review is available when a standard timeline would seriously jeopardize your health — a strong argument for patients with active complement-mediated disease.

## Appeal Process and Timeline

1. Obtain the denial letter and the plan's evidence criteria used to classify Soliris as experimental for this indication. 2. File a written internal appeal citing FDA approval status, the relevant specialty society guidelines (e.g., applicable hematology, nephrology, neurology, or ophthalmology society guidance), and your prescriber's clinical rationale. 3. If internally denied, escalate to external review and request expedited processing if medically urgent.

## Documentation to Gather

• Diagnosis confirmation: Complete diagnostic workup confirming the specific condition (e.g., PNH clone size testing, complement activity assays for aHUS, MG-specific antibody panels, or NMOSD diagnostic imaging and serology as applicable), establishing that the indication matches an FDA-approved use or a recognized guideline-supported use.
• Prescriber medical-necessity letter: A detailed letter from the treating specialist describing the mechanism of disease, why complement inhibition is medically necessary, and citing the relevant professional society guidelines by organization name.
• Prior-treatment history: Documentation of any treatments attempted previously and their outcomes, including why alternative approaches were inadequate.
• Chart documentation: Clinical notes, laboratory trends, and functional assessments demonstrating active disease and urgency of treatment.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy bulletin for Soliris and its definition of experimental/investigational. For each evidentiary criterion, provide a point-by-point response. If the indication is FDA-approved, cite the prescribing label (without reproducing dose numbers) and note the approved indication. If the indication is guideline-supported, identify the guideline organization. Map each coverage requirement to the specific chart fact or clinical document that satisfies it. This systematic mapping is the most effective way to overcome an experimental denial.